Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.19 p - 0.78 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£8.80M
Enterprise Value8.09M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.55
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.32M
Bulls Say, Bears Say
Bulls Say
Proprietary EpiSwitch PlatformOwnership of a proprietary epigenetic EpiSwitch platform provides a durable competitive advantage in biomarker discovery and diagnostics. The platform supports repeatable assays, licensing and partnership opportunities, raising barriers to entry and enabling long-term product and service roadmaps across oncology and autoimmune indications.
Diversified Revenue Streams & CollaborationsMultiple revenue channels—contract research services, licensing, partnerships and potential royalties—reduce reliance on a single product and smooth revenue volatility. Established academic and industry collaborations broaden research capabilities and increase chances of commercialized tests, supporting sustainable revenue generation.
Sustained Revenue GrowthA multi-year positive revenue growth trend (noted at ~22% in the summary) indicates market adoption of services and platform offerings. Persistent top-line growth supports scale economics potential, commercial traction with partners, and the opportunity to leverage fixed R&D and lab costs to improve margins over the medium term.
Bears Say
High LeverageA debt-to-equity ratio of 4.58 signals heavy reliance on debt, which constrains financial flexibility and raises refinancing and interest-rate risk. High leverage can limit capacity to invest in commercialization or R&D, increase bankruptcy risk in stress, and amplify dilution if equity raises are required.
Negative ProfitabilityConsistent negative net margin and negative gross and EBIT margins indicate the company has not yet achieved unit economics or cost control. Ongoing operating losses erode equity, require external financing, and make sustainable profitability dependent on material margin improvement or substantial revenue scaling.
Weak Cash GenerationA -33.93% free cash flow growth and negative operating cash flow relative to net income show the business is burning cash. Poor cash generation reduces runway, increases fundraising frequency, and can delay commercialization and R&D plans, raising long-term execution and dilution risk.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.19 p and its highest was 0.78 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £8.80M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jun 02, 2026 which is in 65 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---